"These are growth stocks where you don't have to worry about disruption. They're breaking out. AI can disrupt a platform overnight; it cannot disrupt a decade-long drug approval process. Large-cap biotech does enjoy a structural insulation from the overnight platform disruption that has hollowed out tech companies."
"The five names he and his colleague highlighted - Amgen, AbbVie, Gilead, Biogen, and Eli Lilly - operate in a domain where competitive moats are built in laboratories over many years, not in data centers over months. A new AI model cannot render a biologic drug obsolete the way it can render a content platform or a search engine irrelevant."
"Large-cap biotech faces its own slow-motion disruption forces - patent cliffs, biosimilar competition, and government drug pricing reform - that are just as capable of destroying revenue. These are different disruption mechanisms, and conflating them leads to blind positions."
Large-cap biotech stocks like Amgen, AbbVie, Gilead, Biogen, and Eli Lilly possess structural protection against the rapid platform disruption that affects technology companies. The FDA drug approval process spanning approximately a decade creates a competitive moat that software companies cannot match. However, biotech faces different disruption mechanisms including patent expirations, biosimilar competition, and government pricing reforms that gradually erode revenue. These companies have demonstrated resilience, with Amgen up 16% and Gilead up 21% year-to-date, outperforming the broader biotech sector. AI is expected to benefit biotech by accelerating drug discovery and clinical trial analysis rather than disrupting existing business models.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]